United Therapeutics Corp (NASDAQ:UTHR)
| CAPS Rating |
|
|---|---|
| Open | $49.12 |
| Previous Close | $49.41 |
| Daily Range | $48.98 - $49.59 |
| 52-Week Range | $36.55 - $70.74 |
| Market Cap | $2.86B |
| P/E Ratio | 16.80 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 555,001 |
| Average Daily Volume | 0 |
UTHR
VS S&P 500 (SPY)
How do you think UTHR will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
UTHR Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
UTHR News and Commentary
- United Therapeutics Earnings Preview – The Motley Fool
- Generic Challenge for UTHR's Remodulin - Analyst Blog – NASDAQ
- United Therapeutics Passes This Key Test – The Motley Fool
- EU Nod for UTHR's Remodulin IV - Analyst Blog – NASDAQ
- Zacks Releases Four Powerful ''Buy'' Stocks: United Therapeutics, Monsanto, Universal and Genesco - – NASDAQ
- United Therapeutics Corp - Aggressive Growth – NASDAQ
- United Therapeutics Enters Oversold Territory - Tale of the Tape – NASDAQ
- The Stocks Wall Street Loves – The Motley Fool
- United Therapeutics to Offer $210M in Debt – Fox Business
- 1 Reason the Street Should Love Gilead Sciences' Earnings – The Motley Fool
- Is United Therapeutics Earning Its Keep? – The Motley Fool
- This Just In: More Upgrades and Downgrades – The Motley Fool
- Why Did My Stock Just Die? – The Motley Fool
- United Therapeutics Plunges on Missed Study Goal – Minyanville
- United Therapeutics Shares Got Crushed: What You Need to Know – The Motley Fool
- United Therapeutics' CEO Discusses Q2 2011 Results - Earnings Call Transcript – SeekingAlpha Transcripts
- Pandora's Debut and J.C. Penney's Genius Hire – The Motley Fool
- 6 High-Growth Stocks With Improving Operating Cash Flow – SeekingAlpha
- Analyst Calls: AET, AKAM, BBY, DVN, HOG, IMAX, LVS, RIMM, UNH, URBN ... – BloggingStocks
- United Therapeutics for Profits and Pipeline – SeekingAlpha
RSS Headlines
Fool UK
